The U.S. Court of Appeals for the Federal Circuit (CAFC) on Tuesday in a precedential decision authored by Judge Taranto affirmed a New Jersey district court’s ruling that Teva Pharmaceuticals USA did not prove the asserted claims of Janssen Pharmaceuticals’ patent for dosing regimens of antipsychotic medications invalid for obviousness.
Recent Posts
- Other Barks & Bites for Friday, August 29: CAFC Affirms Prosecution Laches Ruling Against Hyatt; Trump Admin Cancels USPTO CBA; Second Circuit Affirms Lack of Standing in Ripple Trademark Case
- CAFC Dodges Key Issues in Reversing District Court Finding for Google on Prosecution Laches
- CAFC Corrects PTAB’s Inventorship Analysis in First Appeal of AIA Derivation Proceeding
- Brunetti’s Back: Split CAFC Rejects Most of Scandalous Trademark Applicant’s Arguments But Remands for Second Chance at TTAB
- CAFC is Unconvinced by Claim Construction Challenges to ITC’s Robotics Patent Infringement Finding